Overview

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bivatuzumab mertansine
Maytansine